Search Results
Jun 05, 2026, 16:27 ET HONEYWELL BOARD OF DIRECTORS SETS RECORD DATE AND ANNOUNCES EXPECTED TIMING FOR SPIN-OFF OF HONEYWELL AEROSPACE AND HONEYWELL REVERSE STOCK SPLIT
conditions related thereto; (ii) the possibility that the spin-off transaction will not be completed within the anticipated time period or at all; (iii) the possibility that the spin-off transaction will not achieve its intended benefits; (iv) the impact of the spin-off transaction on Honeywell's businesses
More news about: Honeywell
Jun 05, 2026, 15:02 ET Bitmine Immersion Technologies 宣佈計劃推出 A 系列永續優先股發售
系列優先股的清盤優先權將調整為以下各項中的最高者：(i) 每股 A 系列優先股的設定金額；(ii) 就任何營業日而言，若公司在該營業日或該營業日前十 (10) 個交易日內的任何營業日，曾執行任何需要透過發行 A 系列優先股來結算的出售交易，則金額等於該營業日前一個交易日的每股 A 系列優先股最後申報出售價格；以及 (iii) 該營業日前連續十 (10) 個交易日的每個交易日，其每股 A 系列優先股最後申報出售價格的算術平均值；惟如適用，(iii) 所指的十 (10) 個交易日將改為自初始發行日期（包括該日）起至該營業日（不包括該日）止期間內已過去的較少交易日天數。 然而，清盤優先權不得調整至少於每股 100 美元。BMNR
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 14:41 ET Bitmine Immersion Technologies annuncia la proposta di offerta di azioni privilegiate perpetue di Serie A
diciotto (18) mesi a tre (3) anni dopo la data di emissione originaria, a un prezzo di riscatto pari al 105% dell'importo dichiarato per azione; e (iii) dopo tre (3) anni dalla data di emissione originaria, a un prezzo di riscatto pari al 100% dell'importo dichiarato per azione; più, in ciascun caso,
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 14:38 ET A Bitmine Immersion Technologies anuncia proposta de oferta pública de ações preferenciais perpétuas da Série A
esse dia útil; e (iii) a média aritmética dos últimos preços de venda por ação das Ações Preferenciais da Série A para cada dia de negociação dos dez (10) dias de negociação consecutivos imediatamente anteriores a esse dia útil; contanto, porém, que, se aplicável, a referência em (iii) a dez (10) seja
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 14:35 ET Bitmine Immersion Technologies anuncia una propuesta de emisión de acciones preferentes perpetuas de la Serie A
dieciocho (18) meses hasta tres (3) años a partir de la fecha de emisión original, a un precio de rescate igual al 105 % del importe por acción indicado; y (iii) una vez transcurridos tres (3) años desde la fecha de emisión original, a un precio de rescate igual al 100 % del importe por acción indicado; más,
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 14:19 ET Bitmine Immersion Technologies Umumkan Usulan Penawaran Saham Preferen Perpetual Seri A
tersebut; (iii) rata-rata aritmetika dari harga jual per Saham Preferen Seri A yang terakhir dilaporkan untuk setiap hari perdagangan selama sepuluh (10) hari perdagangan berturut-turut tepat sebelum hari kerja tersebut; dengan ketentuan, jika berlaku, acuan sepuluh (10) hari dalam butir (iii) akan diganti
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 12:00 ET SUBARU EARNS NINE SPOTS ON IIHS AND CONSUMER REPORTS 2026 TEEN DRIVER VEHICLE RECOMMENDATION LIST
ii Models built after 10/2019iii Consumer Reports does not endorse products or servicesAaron ColeProduct Communications Manager856.488.3697
More news about: Subaru of America, Inc.
Jun 05, 2026, 10:38 ET Bitmine Immersion Technologies anuncia el precio de su oferta de acciones preferentes
hábil; y (iii) el promedio aritmético de los últimos precios de venta reportados por acción de Acciones Preferentes Serie A para cada día de negociación de los diez (10) días de negociación consecutivos inmediatamente anteriores a dicho día hábil; sin embargo, si corresponde, la referencia en (iii) a diez
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with
More news about: Vcare PharmaTech
Jun 05, 2026, 09:02 ET New Amsterdam Invest N.V. annual general meeting results
ii. Arie Johannes Maarten van Dam iii. Cornelis Martinus Verkade iv. Elisha
More news about: New Amsterdam Invest N.V.
Jun 05, 2026, 09:00 ET Westland Montana Impact Festival Announces Groundbreaking 2026 Edition
FRUCHT • Bryce Barnes • Kenna Halsey • Matte Wilson • Potlikker Capital • Breanna Schultz • Brigitte Bren • James Brown III • Robert Suarez • Jason Twill • Tele Mike • James Brown, Jr • Offscript Worldwide • Storyhouse • Kaushal
More news about: Westland Impact Festival
Jun 05, 2026, 08:30 ET Bitmine Immersion Technologies Announces Pricing of Upsized Series A Perpetual Preferred Stock Offering
business day; and (iii) the arithmetic average of the last reported sale prices per share of Series A Preferred Stock for each trading day of the ten (10) consecutive trading days immediately preceding such business day; provided, however, that, if applicable, the reference in (iii) to ten (10) will be
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 08:30 ET Bitmine Immersion Technologies Announces Pricing of Upsized Series A Perpetual Preferred Stock Offering
business day; and (iii) the arithmetic average of the last reported sale prices per share of Series A Preferred Stock for each trading day of the ten (10) consecutive trading days immediately preceding such business day; provided, however, that, if applicable, the reference in (iii) to ten (10) will be
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 08:26 ET Bitmine Immersion Technologies Công Bố Đề Xuất Phát Hành Cổ Phiếu Ưu Đãi Vô Thời Hạn Series A
đó; và (iii) giá trị trung bình cộng của giá bán gần nhất được báo cáo trên mỗi cổ phần của Cổ Phiếu Ưu Đãi Series A cho mỗi ngày giao dịch trong mười (10) ngày giao dịch liên tiếp ngay trước ngày làm việc đó. Tuy nhiên, với điều kiện là, nếu thích hợp, việc dẫn chiếu tới mười (10) trong mục (iii) sẽ được
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 08:24 ET Bitmine Immersion Technologies kündigt geplante Emission von unbefristeten Vorzugsaktien der Serie A an
entspricht; und (iii) dem arithmetischen Mittel der zuletzt gemeldeten Verkaufspreise pro Aktie der Vorzugsaktien der Serie A für jeden Handelstag der zehn (10) aufeinanderfolgenden Handelstage unmittelbar vor diesem Geschäftstag; vorausgesetzt jedoch, dass, falls zutreffend, die Bezugnahme in (iii) auf zehn
More news about: Bitmine Immersion Technologies, Inc.
Jun 05, 2026, 08:21 ET Alpha Omega Wins 2026 ACG National Capital Deal of the Year Award
Health and Human Services. The combined organization is also positioned to compete more effectively for large-scale opportunities, including GSA Alliant III and Army MAPS.In 2025, Alpha Omega further strengthened its market position through the development of the
More news about: Alpha Omega
Jun 05, 2026, 07:37 ET YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
the hospitality market across Southeast Asia, Hong Kong, and other markets in which the Company operates, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, (vi) our ability to successfully
More news about: YY Group Holding Limited
Jun 05, 2026, 07:00 ET Trulieve Announces Uplist to NYSE
marijuana to Schedule III paved the way for this historic milestone," said Kim Rivers, Founder and CEO of Trulieve. "Uplisting to the NYSE is a major advancement for Trulieve and the industry."Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III in April 2026, following
More news about: Trulieve Cannabis Corp.
Jun 05, 2026, 06:55 ET Legato Merger Corp. III Shareholders Approve Business Combination with Einride
[email protected] Legato Merger Corp. III Eric Rosenfeld Chief SPAC Officer Legato Merger Corp. III [email protected] This
More news about: Einride
Jun 05, 2026, 06:53 ET Legato Merger Corp. III Shareholders Approve Business Combination with Einride
[email protected] Legato Merger Corp. III Eric Rosenfeld Chief SPAC Officer Legato Merger Corp. III [email protected] This
More news about: Einride
Jun 05, 2026, 06:30 ET Haemonetics Updates Financial Reporting Segments
(ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict
More news about: Haemonetics Corporation
Jun 05, 2026, 06:04 ET Hexagon Composites ASA: Approval of prospectus
May 2026), who (i) were not included in the pre-sounding phase of the Private Placement; (ii) were not allocated shares in the Private Placement and (iii) are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any prospectus filing,
More news about: Hexagon Composites ASA
Jun 05, 2026, 06:00 ET CAE announces renewal of normal course issuer bid
June 10, 2026, and will terminate on the earliest of the date on which: (i) the NCIB expires; (ii) the repurchase limit on the NCIB has been reached; (iii) CAE terminates the ARP in accordance with its terms; and (iv) TD terminates the ARP in accordance with its terms. The ARP constitutes an "automatic
More news about: CAE Inc.
Jun 05, 2026, 01:59 ET Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered
The MDR certification process lasted 2 years and 7 months under the Class III pathway for absorbable implantable medical devices, involving more than 6,381 pages of technical documentation and over 120 internal regulatory meetings.
More news about: Aphranel
Jun 05, 2026, 01:20 ET Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered
The MDR certification process lasted 2 years and 7 months under the Class III pathway for absorbable implantable medical devices, involving more than 6,381 pages of technical documentation and over 120 internal regulatory meetings.
More news about: Aphranel